Anzeige
Mehr »
Login
Dienstag, 24.12.2024 Börsentäglich über 12.000 News von 680 internationalen Medien
Die erste börsennotierte Gesellschaft, die auf das gemeinsame Wachstum von Solana, XRP und Dogecoin setzt!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40EG5 | ISIN: US49721T5074 | Ticker-Symbol: 7EY
NASDAQ
23.12.24
18:27 Uhr
3,180 US-Dollar
0,000
0,00 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
KIORA PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
KIORA PHARMACEUTICALS INC 5-Tage-Chart

Aktuelle News zur KIORA PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
08.11.Kiora Pharmaceuticals GAAP EPS of -$0.81 misses by $0.054
08.11.Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals Reports Third Quarter Results; Retinal Disease Pipeline Advancing Two Phase 2 Studies262Encinitas, California--(Newsfile Corp. - November 8, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced third quarter 2024 financial results and provided...
► Artikel lesen
08.11.KIORA PHARMACEUTICALS INC - 8-K, Current Report2
08.11.KIORA PHARMACEUTICALS INC - 10-Q, Quarterly Report2
29.10.Kiora Pharmaceuticals gets approval to initiate mid-stage trial for eye disorder treatment3
29.10.Kiora Pharmaceuticals schreitet mit Phase-2-Studie zur Wiederherstellung des Sehvermögens voran7
29.10.Kiora Pharmaceuticals advances phase 2 trial for vision restoration2
29.10.KIORA PHARMACEUTICALS INC - 8-K, Current Report3
KIORA PHARMACEUTICALS Aktie jetzt für 0€ handeln
29.10.Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals Receives Investigational New Drug Approval to Initiate ABACUS-2, a Phase 2 Clinical Trial of KIO-301 for the Treatment of Retinitis Pigmentosa209Encinitas, California--(Newsfile Corp. - October 29, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced it received regulatory approval to initiate a Phase...
► Artikel lesen
25.09.Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences344Encinitas, California--(Newsfile Corp. - September 25, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (KPRX) ("Kiora" or the "Company"), will participate in the following investor conferences....
► Artikel lesen
12.09.Kiora Pharmaceuticals director buys shares worth $4,6002
11.09.Kiora Pharmaceuticals director Shapiro Aron buys $10,800 in company stock2
19.08.Kiora Pharmaceuticals director buys $19.8k in company stock8
09.08.Kiora Pharmaceuticals GAAP EPS of -$0.53 beats by $0.332
09.08.KIORA PHARMACEUTICALS INC - 8-K, Current Report2
09.08.Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals Reports Second Quarter Results; Retinal Disease Drug Development Pipeline Advancing Toward Two Phase 2 Studies445Encinitas, California--(Newsfile Corp. - August 9, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") announces second quarter 2024 financial results and provides an update...
► Artikel lesen
09.08.KIORA PHARMACEUTICALS INC - 10-Q, Quarterly Report2
06.08.Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences331Encinitas, California--(Newsfile Corp. - August 6, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (KPRX) ("Kiora" or the "Company"), will participate in two upcoming conferences that will be available...
► Artikel lesen
30.07.KIORA PHARMACEUTICALS INC - 8-K, Current Report1
30.07.Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals Receives European Orphan Medicinal Product Designation for KIO-301 for the Treatment of Inherited Retinal Dystrophies245Encinitas, California--(Newsfile Corp. - July 30, 2024) - Kiora Pharmaceuticals (NASDAQ: KPRX) ("Kiora" or the "Company") today announced it has received Orphan Medicinal Product Designation from the...
► Artikel lesen
Seite:  Weiter >>
40 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1